Variable | SpA group (n= 122) | AS group (n= 95) | nrSpA group (n= 27) | Control group (n= 75) |
---|---|---|---|---|
Male:female ratio (% male) | 90:32 (73.8) | 73:22 (76.8) | 17:10 (63.0) | 42:33 (56.0) |
Age, years | 33.8 [17.3 to 71.6] | 35.7 [17.3 to 71.6] | 27.0 [18.8 to 44.8] | 30.3 [17.7 to 63.8] |
Symptom duration, years | 7.0 [0.3 to 41.0] | 11.0 [0.3 to 41.0] | 1.2 [0.3 to 5.0] | N/A |
HLA-B27-positive, n (%)b | 105/120 (87.5) | 81/93 (87.1) | 24/27 (88.9) | N/A |
BASDAI, NRS range 0 to 10 | 4.4 [0.4 to 9.0] | 4.6 [0.4 to 9.0] | 3.9 [0.8 to 6.3] | N/A |
BASFI, NRS range 0 to 10 | 2.9 [0 to 8.2] | 3.2 [0 to 7.8] | 2.1 [0 to 8.2] | N/A |
BASMI, NRS range 0 to 10 | 1.0 [0 to 8.0] | 1.0 [0 to 8.0] | 0 [0 to 4.0] | N/A |
CRP level, mg/L | 5.0 [0 to 150.0] | 5.0 [0 to 57.0] | 3.0 [0 to 150.0] | N/A |
ESR (mm/hour) | 12.5 [1.0 to 72.0] | 14.0 [2.0 to 69.0] | 8.5 [1.0 to 72.0] | N/A |